Yesterday I started tracing down the effects of cAMP on cancer. I ran across something much more interesting. I knew that CCR5 blockade would downregulate PD-L1 but I didn't know by how much. I had surmised that if it did so very effectively PD-1 inhibitors would be unnecessary. Looking at this study with maraviroc the answer is it downregulates PD-L1 massively. Take into account that maraviroc is most likely less effective at the task then leronlimab. If that combo trial at MD Anderson involves a PD-1 inhibitor than they might as well toss out that inhibitor.



https://jitc.bmj.com/content/8/1/e000228/url]